Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous-to-oral antibiotic switch therapy for suspected neonatal bacterial infections
2016-004447-36Phase 4Completed
- Sponsor
- ROK
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of amoxicillin + clavulanate in neonatal bacterial infection (2 arms), sponsored by ROK. Primary endpoint: Bacterial (re)-infection within 28 days after finishing antimicrobial therapy. Started Feb 2017; status: completed.
02
Drugs
amoxicillin + clavulanate
03
Conditions
neonatal bacterial infection
Beyond the preview
Go deeper on 2016-004447-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004447-36.